Diagram of patient disposition and patient flow through protocol. VAD indicates vincristine plus doxorubicin plus dexamethasone; PAD, bortezomib plus doxorubicin plus dexamethasone; CAD, cyclophosphamide plus doxorubicin plus dexamethasone; and HDM, high-dose melphalan followed by autologous stem cell transplantation.